A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Active, not recruiting · Phase 3 · NCT02107703
Conditions: Breast Neoplasms
At a glance
- Research payments reported, 2025
- $16,776
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 669
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Abemaciclib (drug), Fulvestrant (drug), Placebo (drug)
- Dates
- Started 2014-07-22; completion 2027-12
- Results posted
- Yes
The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant. For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant.
From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $16,776 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Hatem Soliman, MD Hematology & Oncology · Tampa, FL
- Meghna S. Trivedi, MD Medical Oncology · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Moffitt Cancer Center $15,592
- Trustees of Columbia Univ in The City of Ny $1,184
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.